Library Subscription: Guest
Critical Reviews™ in Oncogenesis

Published 4 issues per year

ISSN Print: 0893-9675

ISSN Online: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

Anaplastic Lymphoma Kinase in Human Cancer

Volume 17, Issue 2, 2012, pp. 123-143
DOI: 10.1615/CritRevOncog.v17.i2.10
Get accessGet access

ABSTRACT

The anaplastic lymphoma kinase (ALK) receptor tyrosine kinase is now implicated in a wide range of human cancers. Results from recent clinical trials with ALK inhibitors provide promise for patients harboring oncogenic ALK lesions. This review will discuss our current understanding of ALK in human cancer and the implication of recent results for treatment.

CITED BY
  1. Zimmermann Arthur, Pseudotumors and Related Lesions of the Hepatobiliary Tract, in Tumors and Tumor-Like Lesions of the Hepatobiliary Tract, 2017. Crossref

  2. White Morris F., Receptor Tyrosine Kinases and the Insulin Signaling System, in Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment, 2017. Crossref

  3. White Morris F., Receptor Tyrosine Kinases and the Insulin Signaling System, in Principles of Endocrinology and Hormone Action, 2018. Crossref

  4. Zimmermann Arthur, Pseudotumors and Related Lesions of the Hepatobiliary Tract, in Tumors and Tumor-Like Lesions of the Hepatobiliary Tract, 2016. Crossref

  5. Chang Xing, Wang Junfang, Bian Jiang, Liu Zi, Guo Ming, Li Zengqiang, Wu Yingliang, Zhai Xin, Zuo Daiying, 1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)-3-(2-(dimethylamino)ethyl)imidazolidin-2-one (ZX-42) inhibits cell proliferation and induces apoptosis via inhibiting ALK and its downstream pathways in Karpas299 cells, Toxicology and Applied Pharmacology, 450, 2022. Crossref

Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections Prices and Subscription Policies Begell House Contact Us Language English 中文 Русский Português German French Spain